UBIP has completed the submission for its in-house developed biosimilar drug (UB-851, EPO) to TFDA 2024 年 1 月 2 日 Read More
UBI Pharma Inc.’s “Single-Chain Immunoglobulin Fusion Protein Technology” has been granted a patent in the USA 2023 年 12 月 6 日 Read More
Merdury Biopharmaceutical Corporation Partners with UBI Pharma Inc.(6562.TW) to Pioneer Sildenafil Orally Disintegrating Tablets for the $4.5 Billion Global ED Drug Market 2023 年 11 月 14 日 Read More
UBI Pharma Inc. as received two prestigious awards at the 20th National Brand Yushan Awards (2023) 2023 年 10 月 25 日 Read More
UBI Pharma Inc. has commissioned EirGenix to produce the biosimilar drug UB-851, paving the way for an early international market expansion. 2023 年 10 月 3 日 Read More
UBI Pharma Inc. Passes Ukrainian Inspection, Joining Lumosa Therapeutics to Enter European Market 2023 年 7 月 24 日 Read More